

## Special Issue

# Infection Diagnostics and Antimicrobial Therapy for Critical Patient

### Message from the Guest Editor

A prompt and correct antibacterial therapy affects the mortality of critical patients. New diagnostic methods are available for a faster diagnosis than conventional techniques to start targeted antimicrobial therapy.

Targeted therapy also reduces the risk of developing multidrug-resistant (MDR) bacteria. MDR bacteria are a major issue in many hospitals, especially in ICUs with in-hospital outbreaks and increased mortality. This Special Issue seeks manuscript submissions that further our understanding of diagnostic and antimicrobial therapy in critical patients. Submissions on new microbiological techniques (PCR: film array) in critical patients, adequate dosage of antibacterials in this setting with the support of therapeutic drug monitoring, and antibacterial therapy in difficult-to-treat bacteria in this setting (i.e., *Stenotrophomonas*, MDR *Enterobacteria*, *Acinetobacter*) are especially encouraged.

---

### Guest Editor

Dr. Giovanna Travi

Asst Grande Ospedale Metropolitano Niguarda, Milan, Italy

---

### Deadline for manuscript submissions

closed (30 April 2025)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.6**  
**CiteScore 8.7**  
**Indexed in PubMed**



[mdpi.com/si/175465](https://mdpi.com/si/175465)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)